KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) EBT (2016 - 2025)

NovoCure's EBT history spans 12 years, with the latest figure at -$41.0 million for Q4 2025.

  • For Q4 2025, EBT rose 25.82% year-over-year to -$41.0 million; the TTM value through Dec 2025 reached -$136.2 million, down 3.88%, while the annual FY2025 figure was -$136.2 million, 3.88% down from the prior year.
  • EBT for Q4 2025 was -$41.0 million at NovoCure, down from -$30.0 million in the prior quarter.
  • Across five years, EBT topped out at -$2.5 million in Q1 2022 and bottomed at -$55.2 million in Q4 2024.
  • The 5-year median for EBT is -$30.2 million (2025), against an average of -$29.7 million.
  • The largest annual shift saw EBT plummeted 1931.01% in 2023 before it soared 57.83% in 2024.
  • A 5-year view of EBT shows it stood at -$25.6 million in 2021, then dropped by 27.31% to -$32.6 million in 2022, then decreased by 18.35% to -$38.5 million in 2023, then crashed by 43.27% to -$55.2 million in 2024, then grew by 25.82% to -$41.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's EBT are -$41.0 million (Q4 2025), -$30.0 million (Q3 2025), and -$35.0 million (Q2 2025).